

camh

Opioid Agonist Therapy:

A Prescriber's Guide to Treatment

Coming in spring 2022

3rd edition—formerly Methadone Maintenance: A Physician's Guide to Treatment

Edited by Peter Selby, Launette Rieb, Vincent Lam, Maria Zhang and Jonathan Bertram

Paperback = 289 pages + index = \$69.95 = Published 2022 = ISBN: 978-1-77114-443-8 (print) = Product code: P6528

Health care providers play a key role in addressing Canada's opioid use crisis. *Opioid Agonist Therapy: A Prescriber's Guide to Treatment* is a comprehensive, practical resource that supports the work of care providers such as physicians and nurse practitioners who are authorized to prescribe medications to treat opioid use disorder.

This expanded and updated edition reflects the latest evidence and practices that have evolved since *Methadone Maintenance: A Physician's Guide to Treatment* was published in 2011—before buprenorphine and other pharmacological options became available to meet the varying needs of people with opioid use disorder.

This guide is relevant to both practitioners working in primary care and those who focus on addiction medicine. With contributions from more than 50 experts across Canada, it highlights clinically tested guidance on treating opioid use disorder and provides essential information on topics such as:

- prescribing and administering methadone, buprenorphine, slow-release oral morphine and injectable OAT (diacetylmorphine and hydromorphone)
- safety considerations and drug interactions
- take-home dosing and urine drug testing
- OAT with specific populations (pregnancy, chronic pain, psychiatric disorders, HIV and hepatitis C, Indigenous people, youth, older adults)
- continuity of care for patients who have been hospitalized or incarcerated.

ABOUT THE EDITORS

Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Senior medical consultant and clinician scientist, Addictions, CAMH; director, Mental Health and Addictions Division, Department of Family and Community Medicine, University of Toronto

Launette Rieb, MD, MSc, CCFP (AM), FCFP, CCSAM, DipABAM, FASAM, Pain and addiction medicine consultant, Actum Health, Surrey, BC; and Rapid Access Addictions Clinic, St. Paul's Hospital, Vancouver

Vincent Lam, MD, CCFP (AM), Medical director, Coderix Medical Clinic, Toronto; lecturer, Department of Family and Community Medicine, University of Toronto

Maria Zhang, RPh, BScPhm, PharmD, MSc, Advanced practice clinical leader (Pharmacy), CAMH; clinician educator, Leslie Dan Faculty of Pharmacy, University of Toronto

Jonathan Bertram, MD, CCFP (AM), Addictions physician, CAMH; addictions and pain physician, Clarington Family Health Organization; lecturer, Department of Family and Community Medicine, University of Toronto

To place an order, please contact

CAMH Publications

store.camh.ca

publications@camh.ca Toll-free: 1 800 661-1111 Toronto: 416 595-6059

TABLE OF CONTENTS

SECTION I: FUNDAMENTAL CONCEPTS AND APPROACHES IN OPIOID AGONIST THERAPY

1 Opioid pharmacology and history

Emily Kendell

2 Key concepts and theories of addiction

Osnat C. Melamed, Peter Selby and Sara Ling

3 Opioid use disorder

Dania Notta

4 Harm reduction

Brandon Yau, Wendy Stevens, Emily Wagner, Josey Ross, Cheyenne Johnson and Christy Sutherland

5 Foundations of care and OAT provider roles

Rosanra Yoon, Annabel Mead, Sara Ling and Maria Zhang

SECTION II: TREATMENT OF OPIOID USE DISORDER

6 OAT overview and impact on daily life

Paxton Bach and Charl Els

7 Pharmacological treatment of opioid use disorder

Seonaid Nolan, Christy Sutherland, Josey Ross, Evan Wood, M. Eugenia Socias, Wallace Yuen and Paxton Bach

8 Psychosocial interventions for opioid use disorder

Rosanra Yoon and Vincent Lam

SECTION III: OPIOID AGONIST THERAPY PRESCRIBING PROTOCOLS AND GUIDELINES

9 Comprehensive assessment for OAT

Dania Notta

10 OAT prescription standards and requirements

Maria Zhang

11 Buprenorphine and methadone dosing

Vincent Lam

12 Slow-release oral morphine

Pamela Kaduri

13 Injectable opioid agonist therapy

Scott Macdonald and Eugenia Oviedo-Joekes

14 Combination OAT and rotation

Sarah Whynot and Nikki Bozinoff

15 Urine drug testing

Cristiana Stefan

16 Take-home dosing

Vincent Lam

17 Tapering OAT

Vincent Lam

18 Termination of OAT

Vincent Lam

19 Management of opioid overdose

Michelle Klaiman and Alexander Caudarella

SECTION IV: CLINICAL ISSUES IN OPIOID AGONIST THERAPY

20 Chronic pain and opioid use disorder

Robert L. Tanguay, Joel Bordman, Hance A. Clarke, Launette M. Rieb and Owen D. Williamson

21 Concurrent mental health disorders

Ahmed N. Hassan

22 Concurrent substance use and OAT

Francesca di Paola, Olivia Margie and Peter Selby

23 HIV and hepatitis C

Neal Belluzzo, Kathryn Dorman, Maya Nader and James Owen

24 Pregnancy and OAT

Alice Ordean

25 Neonatal abstinence syndrome

Alice Ordean

26 OAT across the lifespan

Sharon Cirone and Jonathan Bertram

SECTION V: OPIOID AGONIST THERAPY IN MARGINALIZED POPULATIONS AND SPECIFIC SETTINGS

27 Social determinants of health and opioid use disorder

Alyssa Kelly and S. Monty Ghosh

28 Poverty and opioid use disorder

Larisa Eibisch

29 OAT with First Nations communities

Jacqueline Nokusis, Lisa Richardson and Renee Linklater

30 Women and opioid use disorder

Annabel Mead

31 OAT in institutional settings

Robert McMaster, Michelle Klaiman and Alexander Caudarella

32 OAT in rural and remote settings

Melissa Holowaty and Peter Selby